featured-image

CRISPR Therapeutics ( NASDAQ: CRSP ) has announced the appointment of Naimish Patel, M.D., as CMO, effective May 28, 2024.

Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Co.



also announced the promotion of Julianne Bruno, M.B.A.

, to COO, effective as of May 23, 2024. More on CRISPR Therapeutics CRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript) Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade) Bluebird bio spikes even as CRISPR leads in gene therapy rollout TD Cowen says sickle cell therapies may get higher CMS payments.

Back to Health Page